Medical Condition News

RSS

Brain hypoxia associated with poor short-term outcome after severe TBI

Low oxygen supply (hypoxia) to vulnerable brain tissue is a major contributor to the risk of death or major disability after severe traumatic brain injury (TBI), reports a study in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

9 Nov 2011

More than 3 million Americans quit smoking every year

The United States is winning the war against smoking. More than 3 million Americans quit smoking every year and fewer are adopting the unhealthy and expensive habit.

9 Nov 2011

Svelte initiates Rapamycin-eluting stent with bio-Eroding Carrier Technology implantation study

Svelte Medical Systems today announced treatment of the first patient in the DIRECT (Direct-on-a-wire Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study at Auckland City Hospital in Auckland, New Zealand.

9 Nov 2011

Highmark now covers AlloMap for monitoring heart transplant rejection

XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive diagnostic tests to monitor immune-mediated conditions, today announced that Highmark Inc., an independent licensee of the Blue Cross Blue Shield Association, is now covering AlloMap for its beneficiaries.

9 Nov 2011

Viagra may improve antitumor immunity in people with melanoma

At first it sounds like good news: The body's own immune system gets active in almost every cancer - however, not necessarily for the benefit of the patient. "We distinguish between two different types of immune response," says Professor Dr. Viktor Umansky, immunologist at DKFZ and University Medical Center Mannheim. "On the one hand, cells of the immune system specifically attack tumor cells.

9 Nov 2011

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Pfizer Inc. announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency.

9 Nov 2011

Semtech to donate $25,000 for new UCLA cancer treatment center

Semtech Corporation, a leading supplier of analog and mixed-signal semiconductors, today announced it will contribute $25,000 to the UCLA Hospital System toward the development of a new treatment center at the Ronald Reagan UCLA Medical Center for teen and young adult cancer patients.

9 Nov 2011

Men and overweight individuals eat faster, consume more

Two new studies by researchers at the University of Rhode Island are providing additional insights into the role that eating rate plays in the amount of food one consumes. The studies found that men eat significantly faster than women, heavier people eat faster than slimmer people, and refined grains are consumed faster than whole grains, among other findings.

9 Nov 2011

Inhaling low levels of CO reduces impact of environmental stress

According to scientists, carbon monoxide (CO), a tasteless, colorless and odorless gas, is not only a danger to the environment but also highly toxic to human beings. Found in the exhaust of vehicles and generators, CO has been dubbed the "silent killer" because excessive inhalation is lethal, poisoning the nervous system and heart.

9 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

Cancer specialists struggling to find better screening tests

With new concern about whether consumers should be tested for some cancers -- especially those that are slow growing -- researchers are working to find more specific tests and advice that can be helpful.

9 Nov 2011

FOBt-based colorectal cancer screening programme cuts death rate by 27%

Bowel screening reduces the number of deaths from bowel cancer in Scotland by more than 25 per cent, according to research* presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool this week.

9 Nov 2011

QRxPharma receives FDA written acceptance for review of MoxDuo IR NDA

QRxPharma Limited announced today it received written acceptance from the United States Food and Drug Administration (FDA) for review of the MoxDuo IR New Drug Application (NDA) filed earlier this year.

9 Nov 2011

Prognomix, Servier enter R&D agreement to identify novel type 2 diabetes targets

Les Laboratoires Servier, France (Servier) and Prognomix Inc., Canada (Prognomix) announced today that they have entered into a research and development agreement aimed at identifying novel targets as part of programs meant to develop innovative type 2 diabetes and metabolic disease treatment.

9 Nov 2011

Almac devises new test to detect likelihood of colon cancer recurring

Northern Ireland-based pharmaceutical development company Almac has devised a groundbreaking new test which can detect the likelihood of the recurrence of stage 2 colon cancer in patients who have undergone surgery.

9 Nov 2011

University of Houston to enhance cancer research facilities

Thanks to almost $1 million in new funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Houston (UH) will soon be enhancing its cancer research facilities.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 - 13 in San Diego, California.

9 Nov 2011

Boston Scientific reports positive long-term data from PERSEUS clinical program

Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.

9 Nov 2011